Table 1.
Characteristics of the included meta-analyses evaluating soy-based interventions and plasma lipid profiles in postmenopausal womena.
| Reference | No. of studiesb | Sample sizeb | Intervention | Intervention dose | Intervention period (week) | Comparison | Outcome |
|---|---|---|---|---|---|---|---|
| Yeung et al. (32) | 17 | 853 | Mixed (isoflavones, isolated soy protein) | NA | 2–26 | Placebo | TC |
| Zhan et al. (33) | 23 | 1,381 | Soy protein containing isoflavones | Isoflavone concentrations averaged 80 mg/d | 3–26 | Control | TC |
| Taku et al. (31) | 19 | 349 | Extracted soy isoflavones | Average: 70 mg/day Range: 27–132 mg/day | 4–13 | Placebo | LDL-C |
| Moradi et al. (34) | 52 | 3,456 | Soy product | Soy protein: 2–45 g/day | 6–96 | Placebo | TG, TC, LDL-C, HDL-C, Apolipoprotein A-1, Apolipoprotein B |
| Bara'nska, et al. (28) | 29 | 2,305 | Soy isoflavone extracts and soy protein containing isoflavones | Isoflavones: overall average 87.6 mg/d (median: 80 mg; range: 30.3 to 165 mg) | 12 | Placebo | TC, TAG, LDL-C, HDL-C |
| Qi et al. (30) | 29 | 2,457 | Unfermented soy product consumption | NA | 4–96 | Diets without unfermented soy products | TC, TG, LDL-C, HDL-C |
| Park et al. (29) | 61 | 6,s127 | Soy isoflavone | Soy isoflavone: range (40–165 mg/d) | 12–144 | Placebo | TC, TG, LDL-C |
HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TAG, Triacylglycerol; TC, Total cholesterol; TG, Triglycerides. aEligible soy-specific/postmenopausal subgroup extracted in this umbrella review; bNumbers of studies and participants refer to the overall source meta-analysis.